RSV INFECTION

This early-stage study tested two versions of a new RSV vaccine given as nose drops in young children. The main goals were to check if the weakened virus in the vaccine was safe, if it caused a minor infection to trigger immunity, and how well children's immune systems responded.…

This first-in-human study tested the safety and immune response of a new vaccine designed to protect against two common respiratory viruses, RSV and hMPV, in adults aged 60 to 75. 385 participants received a single injection of either the combined vaccine or an RSV-only vaccine a…

This study tested if a new oral medication called EDP-323 could safely reduce Respiratory Syncytial Virus (RSV) in healthy adults. Researchers intentionally exposed 142 healthy volunteers to RSV and gave them either the drug or a placebo pill. The main goal was to see if the drug…

This study tested a new preventive antibody drug called clesrovimab to see if it is safe and works as well as the standard treatment (palivizumab) for preventing severe RSV disease. It involved over 1,000 infants and children who are at high risk for serious RSV infections. Resea…

This study aimed to understand why older adults are more vulnerable to severe RSV infections by comparing their immune responses to younger people. Researchers intentionally gave a controlled RSV infection to 28 healthy older volunteers (ages 60-75) and monitored their immune cel…